After enduring cardiopulmonary bypass, many patients experience an inflammatory response, which can lead to prolonged ventilation, bleeding, stroke, and renal dysfunction. The NewYork-Presbyterian and Weill Cornell Medicine trial center was chosen to further investigate RBT-1 to see if it can help the production of anti-inflammatory cytokines and reduce the occurrence of common post-surgical complications. Researchers found that patients who received RBT-1 had a 46 percent decrease in blood product transfusions, a lower likelihood of readmission to the hospital within 30 days, and spent less time in the ICU and on a ventilator.